anonymous
Guest
anonymous
Guest
That's what we sell siders are trying to discount. Clearly, Otezla, with it's lack of data, requires huge volumes of sales presentations by reps. Nothing else moves the needle. The Amgen culture prohibits that. With the thousands of teleconferences, training meetings, out of field meetings, and other activity driven metrics, how quickly will Otezla acquire Enbrel's negative growth rate?